By Alex Kanarek (akanarek
bptc
com) and Howard Levine (hlevinebptccom)
Since the issue of its cGMP Initiative in 2002, FDA has concentrated on applying risk-evaluation techniques to the various procedures involved in new drug approval. Following this trend, the agency recently issued a completely revised Compliance Guidance Manual on Pre-Approval Inspections for use by field staff.
